| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097711A2 Treatment of pulmonary hypertension |
| 05/09/2001 | EP1097698A2 Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097147A1 Novel angiogenesis inhibitors |
| 05/09/2001 | EP1097142A1 Phthalazine derivatives phosphodiesterase 4 inhibitors |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097127A1 Diacylhydrazine derivatives as integrin inhibitors |
| 05/09/2001 | EP1096945A1 Lysine binding fragments of angiostatin |
| 05/09/2001 | EP1096944A1 Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them |
| 05/09/2001 | EP1096943A1 Method of preparation and pharmaceutical composition of an uncaria water soluble extract |
| 05/09/2001 | EP1096938A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide |
| 05/09/2001 | EP0633776B1 Compounds useful for treating allergic and inflammatory diseases |
| 05/09/2001 | CN1294590A Method of 3-substituted adenines via 2-thioxanthines |
| 05/09/2001 | CN1294579A Sulfonamide-contg. indole compounds |
| 05/09/2001 | CN1293989A Liquid Chinese medicine for treating rheumatism |
| 05/09/2001 | CN1293988A Chinese medicine 'Shexianfengshi wan' |
| 05/09/2001 | CN1293984A Medical wind for treating rheumatism |
| 05/09/2001 | CN1293976A Composite Chinese medicine for treating diseases caused by wind and cold |
| 05/09/2001 | CN1293957A Non-steroid antiinflammatory |
| 05/09/2001 | CN1065438C Cyclic adhesion inhibitors |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6228889 Methods for treatment of conditions associated with lactosylceramide |
| 05/08/2001 | US6228881 Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
| 05/08/2001 | US6228859 Antiasthmatic, antiinflammatory, antiallergen and antidepressant agents |
| 05/08/2001 | US6228853 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228642 Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228373 Peptide dimer, glycine, cystine or prolne amino acid for immunology |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2032330C Benzyl-substituted rhodanine derivatives for treating inflammatory bowel disease |
| 05/08/2001 | CA2029694C Heteroatoms-containing tricyclic compounds |
| 05/08/2001 | CA2017746C A new phenylacetic derivative and process for their obtention |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030778A1 Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
| 05/03/2001 | WO2001030777A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030768A1 Methods and compositions utilizing quinazolinones |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030747A1 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
| 05/03/2001 | WO2001030734A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030386A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030338A2 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation |
| 05/03/2001 | WO2001030334A2 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |
| 05/03/2001 | WO2001030333A2 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | WO2001030330A2 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2000074712A3 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 05/03/2001 | WO2000074695A3 Tanacetum parthenium extract |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000068263A3 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 05/03/2001 | WO2000066107A3 Antimalarian agents for the treatment of asthma |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE19949202A1 Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure Transdermal therapeutic system for the delivery of acetylsalicylic acid and / or salicylic acid |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2389319A1 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
| 05/03/2001 | CA2389181A1 6-methoxy-2-napthylacetic acid prodrugs for treating inflammation |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388934A1 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2388119A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | CA2387889A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | CA2387857A1 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2387098A1 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2386441A1 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096016A1 Platelet-activating factor acetylhydrolase |
| 05/02/2001 | EP1096009A1 G-protein coupled receptor-like Polypeptide |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095936A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| 05/02/2001 | EP1095933A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095658A2 Use of ribose to treat fibromyalgia |
| 05/02/2001 | EP1095657A2 Compositions for the regulation of cytokine activity |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095061A1 Peptides based on the sequence of human lactoferrin and their use |